

# Decoding AR-associated resistance in advanced prostate cancer: From biology to emerging therapeutics

Palazzo dei Congressi • Room B1 • Lugano, Switzerland

Tuesday, 28 April 2026 • 18:30 - 20:00 (CEST)

## Chair



**Kim Chi**  
Executive Vice President,  
Chief Medical Officer  
Provincial Health Services  
Authority - BC Cancer  
Vancouver, Canada

## Faculty



**Gerhardt Attard**  
Director  
University College London  
Cancer Institute  
London, United Kingdom



**Himisha Beltran**  
Professor of Medicine  
Lank Center for Genitourinary Oncology  
Dana-Farber Cancer Institute  
Boston, Massachusetts, USA



**Alice Bernard-Tessier**  
Assistant Professor  
Institute Gustave Roussy  
Villejuif, France



**Shahneen Sandhu**  
Consultant  
Peter MacCallum Cancer Centre  
Melbourne, Australia

## Agenda

18:30 - 18:40	Welcome and open <i>Kim Chi</i>
18:40 - 18:55	Mechanisms of resistance to ARPIs: Are all AR aberrations similar? <i>Gerhardt Attard</i>
18:55 - 19:10	Defining AR-associated resistance: What to test and when? <i>Himisha Beltran</i>
19:10 - 19:20	Faculty panel discussion <i>Moderated by Kim Chi</i>
19:20 - 19:35	From lab to the clinic: What are the current options in the post-ARPI setting? Reinforcing shared decision-making <i>Shahneen Sandhu</i>
19:35 - 19:50	Targeting AR: Emerging options in the post-ARPI setting <i>Alice Bernard-Tessier</i>
19:50 - 20:00	Q&A and panel discussion <i>Moderated by Kim Chi</i>
20:00	Closing remarks <i>Kim Chi</i>

Agenda may be subject to change pending speaker confirmation

## Symposium sponsored by MSD

This program is not intended for healthcare professionals who practice in, are licensed to practice in, or reside in the U.K. and the U.S., its territories, or Puerto Rico.

Copyright © 2026 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. HQ-NON-01385 04/26 W8000545

